Infertility Drugs Market Report by Drug Class (Gonadotropin, Aromatase Inhibitors, Selective Estrogen Receptor Modulators, Biguanides, and Others), Route of Administration, Distribution Channel, End User, and Region 2024-2032
세계 불임 치료제 시장 규모는 2023년 39억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년 4.7%의 연평균 성장률(CAGR)을 보이며 2032년까지 60억 달러에 달할 것으로 예상하고 있습니다.
불임 치료제는 불임증을 치료하고 개인의 생식 기능을 향상시키기 위해 사용되는 다양한 약물을 말합니다. 불임 치료제는 주사 또는 경구 투여됩니다. 일반적으로 사용되는 불임 치료제는 성선자극호르몬, 아로마타제 억제제, 선택적 에스트로겐 수용체 조절제(SERM), 비구아나이드 계열 약물, 배란 촉진제, 도파민 작용제, 삼환계 항우울제 등이 있습니다. 이 약들은 여성의 경우 난소의 배란과 난포 발달을 자극하여 작용하며, 남성의 경우 테스토스테론 수치를 회복시키고 정자의 질을 개선하여 임신을 유도합니다. 최근 몇 년 동안 불임 치료제는 임신을 할 수 없는 부부들 사이에서 인기를 끌고 있습니다.
불임 치료제 시장 동향:
불임 치료제는 임신에 기여하는 개인의 능력을 회복시켜 부부의 임신 가능성을 높이는 데 도움을 줍니다. 그 결과, 불임과 유산의 증가가 시장 성장의 주요 요인으로 작용하고 있습니다. 이와 더불어, 각국 정부가 가용한 치료 옵션에 대한 인식을 높이기 위해 취한 여러 가지 긍정적인 노력은 불임 치료제에 대한 수요를 자극하고 있습니다. 또한, 바쁜 업무 일정과 그에 따른 스트레스, 라이프스타일의 변화로 인해 암, 비만, 당뇨병, 갑상선, 다낭성난소증후군(PCOS), 폐경과 같은 만성 질환의 유병률이 크게 증가하고 있습니다. 여기에 임신 지연, 만혼화, 알코올 및 약물 과다 복용, 흡연과 같은 건강에 해로운 습관으로 인한 출산율 저하가 제품 채택률을 가속화하고 있습니다. 또한, 여러 주요 기업들이 연구개발(R&D) 활동을 통해 효능이 강화되고, 복용량이 적고, 부작용이 적은 혁신적인 불임 치료제를 출시하고 있습니다. 또한, 이러한 약물 개발을 위한 공공 자금의 증가와 다양한 규제 기관의 신속한 약물 승인은 시장 성장을 촉진하고 있습니다. 제네릭 의약품에 대한 수요 증가, 의료 인프라 개선, 소비 지출 능력 증가, 급속한 도시화, 기술 발전과 같은 다른 요인들도 시장 성장을 촉진하고 있습니다.
본 보고서에서 다루는 주요 질문들
- 세계 불임 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
- COVID-19가 세계 불임 치료제 시장에 미치는 영향은?
- 주요 지역 시장은?
- 약제 종류별 시장 현황은?
- 투여 경로별 시장 현황은?
- 판매 채널별 시장 현황은?
- 최종사용자별 시장 분석은?
- 산업 가치사슬의 다양한 단계는 무엇인가?
- 업계의 주요 촉진요인과 과제는 무엇인가?
- 세계 불임 치료제 시장 구조와 주요 진출 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 불임 치료제 세계 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 약제 클래스별
- 성선자극호르몬
- 아로마타제 억제제
- 선택적 에스트로겐 수용체 모듈레이터(SERMs)
- 비구아니드
- 기타
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 유통 채널별
제9장 시장 내역 : 최종사용자별
제10장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Abbott Laboratories
- Bayer AG
- Ferring Pharmaceuticals
- Livzon Pharmaceutical Group Inc.
- Mankind Pharma
- Merck & Co. Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Theramex
ksm
The global infertility drugs market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032.
Infertility drugs refer to various medications used to treat infertility and enhance the reproductive health of an individual. They are either injected or taken orally. Some commonly used infertility drugs include gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, ovulatory stimulants, dopamine agonists, and tricyclic antidepressants. They work by stimulating ovulation and follicle development of the ovary in women, whereas they help restore testosterone levels and improve the quality of sperm in men to bring about pregnancy. In recent years, infertility drugs have gained traction among couples who are unable to conceive.
Infertility Drugs Market Trends:
Infertility drugs assist in enhancing the chances of pregnancy in couples by restoring the ability of an individual to contribute to conception. As a result, the rising incidences of infertility and miscarriage represents the primary factor driving the market growth. Besides this, several favorable initiatives undertaken by governments of various countries to spread awareness regarding the available treatment options are catalyzing the demand for infertility drugs. Additionally, there has been a significant increase in the prevalence of chronic diseases, such as cancer, obesity, diabetes, thyroid, polycystic ovarian syndrome (PCOS), and menopausal disorders, on account of hectic work schedules, accompanying stress, and lifestyle changes. Along with this, the declining fertility rates due to delayed pregnancies, late marriages, and unhealthy habits, such as excessive consumption of alcohol, drugs, and smoking, are accelerating the product adoption rates. Furthermore, several key players are engaging in research and development (R&D) activities to launch innovative infertility drugs with enhanced efficacy, lower dosage requirements, and fewer side effects. Moreover, the increasing public funding for developing these drugs and faster drug approvals from various regulatory bodies are propelling the market growth. Other factors, including the escalating demand for generic medicines, improving healthcare infrastructure, rising consumer expenditure capacities, rapid urbanization, and technological advancements, are also providing a positive thrust to the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global infertility drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration, distribution channel and end user.
Breakup by Drug Class:
Gonadotropin
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Others
Breakup by Route of Administration:
Oral
Intravenous
Subcutaneous
Intramuscular
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Breakup by End User:
Male
Female
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex.
Key Questions Answered in This Report:
- How has the global infertility drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global infertility drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global infertility drugs market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Infertility Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Class
- 6.1 Gonadotropin
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Aromatase Inhibitors
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Selective Estrogen Receptor Modulators (SERMs)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Biguanides
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intravenous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Subcutaneous
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Intramuscular
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End User
- 9.1 Male
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Female
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.2 Bayer AG
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Ferring Pharmaceuticals
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Livzon Pharmaceutical Group Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Mankind Pharma
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Merck & Co. Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 Merck KGaA
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Novartis AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Theramex
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
